Joanna Shields, BenevolentAI CEO

AI tools don't equal guar­an­teed drug suc­cess as Benev­o­len­tAI flops der­mati­tis test

It’s a no for BEN.

BEN-2293, a top­i­cal out of Lon­don-based Benev­o­len­tAI, has failed sec­ondary ef­fi­ca­cy mea­sures in a Phase IIa …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.